However, in 1993, results from a randomized trial of 181 patients with advanced melanoma or renal cancer comparing treatment with IL-2 alone or in conjunction with LAK cells showed that the observed anti-tumor effects tended to be due to IL-2 alone (66), thereby hampering clinical studies of LAK cells. Here, IL2 is linked to melanoma.